Skip to main content

Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis.

Publication ,  Journal Article
Di Stefano, L; Ogburn, EL; Ram, M; Scharfstein, DO; Li, T; Khanal, P; Baksh, SN; McBee, N; Gruber, J; Gildea, MR; Clark, MR; Goldenberg, NA ...
Published in: PLoS One
2022

BACKGROUND: Results from observational studies and randomized clinical trials (RCTs) have led to the consensus that hydroxychloroquine (HCQ) and chloroquine (CQ) are not effective for COVID-19 prevention or treatment. Pooling individual participant data, including unanalyzed data from trials terminated early, enables more detailed investigation of the efficacy and safety of HCQ/CQ among subgroups of hospitalized patients. METHODS: We searched ClinicalTrials.gov in May and June 2020 for US-based RCTs evaluating HCQ/CQ in hospitalized COVID-19 patients in which the outcomes defined in this study were recorded or could be extrapolated. The primary outcome was a 7-point ordinal scale measured between day 28 and 35 post enrollment; comparisons used proportional odds ratios. Harmonized de-identified data were collected via a common template spreadsheet sent to each principal investigator. The data were analyzed by fitting a prespecified Bayesian ordinal regression model and standardizing the resulting predictions. RESULTS: Eight of 19 trials met eligibility criteria and agreed to participate. Patient-level data were available from 770 participants (412 HCQ/CQ vs 358 control). Baseline characteristics were similar between groups. We did not find evidence of a difference in COVID-19 ordinal scores between days 28 and 35 post-enrollment in the pooled patient population (odds ratio, 0.97; 95% credible interval, 0.76-1.24; higher favors HCQ/CQ), and found no convincing evidence of meaningful treatment effect heterogeneity among prespecified subgroups. Adverse event and serious adverse event rates were numerically higher with HCQ/CQ vs control (0.39 vs 0.29 and 0.13 vs 0.09 per patient, respectively). CONCLUSIONS: The findings of this individual participant data meta-analysis reinforce those of individual RCTs that HCQ/CQ is not efficacious for treatment of COVID-19 in hospitalized patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2022

Volume

17

Issue

9

Start / End Page

e0273526

Location

United States

Related Subject Headings

  • Hydroxychloroquine
  • Humans
  • General Science & Technology
  • Data Analysis
  • Chloroquine
  • COVID-19 Drug Treatment
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Di Stefano, L., Ogburn, E. L., Ram, M., Scharfstein, D. O., Li, T., Khanal, P., … Pandemic Response COVID-19 Research Collaboration Platform for HCQ/CQ Pooled Analyses, . (2022). Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. PLoS One, 17(9), e0273526. https://doi.org/10.1371/journal.pone.0273526
Di Stefano, Leon, Elizabeth L. Ogburn, Malathi Ram, Daniel O. Scharfstein, Tianjing Li, Preeti Khanal, Sheriza N. Baksh, et al. “Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis.PLoS One 17, no. 9 (2022): e0273526. https://doi.org/10.1371/journal.pone.0273526.
Di Stefano L, Ogburn EL, Ram M, Scharfstein DO, Li T, Khanal P, et al. Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. PLoS One. 2022;17(9):e0273526.
Di Stefano, Leon, et al. “Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis.PLoS One, vol. 17, no. 9, 2022, p. e0273526. Pubmed, doi:10.1371/journal.pone.0273526.
Di Stefano L, Ogburn EL, Ram M, Scharfstein DO, Li T, Khanal P, Baksh SN, McBee N, Gruber J, Gildea MR, Clark MR, Goldenberg NA, Bennani Y, Brown SM, Buckel WR, Clement ME, Mulligan MJ, O’Halloran JA, Rauseo AM, Self WH, Semler MW, Seto T, Stout JE, Ulrich RJ, Victory J, Bierer BE, Hanley DF, Freilich D, Pandemic Response COVID-19 Research Collaboration Platform for HCQ/CQ Pooled Analyses. Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. PLoS One. 2022;17(9):e0273526.

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2022

Volume

17

Issue

9

Start / End Page

e0273526

Location

United States

Related Subject Headings

  • Hydroxychloroquine
  • Humans
  • General Science & Technology
  • Data Analysis
  • Chloroquine
  • COVID-19 Drug Treatment